Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Updated Investor Presentation
View:
Post by Pareto8020 on Nov 03, 2020 8:24am

Updated Investor Presentation

https://www.sironabiochem.com/wp-content/uploads/2020/11/SBM-Investor-Presentation-November2020.pdf

They checked off the "Publish in a reputable journal" box.  

Which leaves the following heavy lifting for Howard and crew to complete:

•Finalize the Beijing Huaxi Pharma Co, Ltd. collaboration agreement
•Complete an additional licensing agreement for the SGLT2 inhibitor in new markets
•Secure non dilutive funding through anticipated collaborations
•Finalize Tinyi agreement
•Complete a clinical trial for an increased dose of TFC 1067 (.4 %)
•Complete Phase I clinical trial in China for the SGLT2 Inhibitor and advance to Phase II
•Complete safety studies and enter clinical trial for anti wrinkle compound
•Develop new anti viral compounds and advance them into preclinical studies

 
Comment by lscfa on Nov 03, 2020 10:18am
How about adding an item - generate revenues
Comment by Crazydan on Nov 03, 2020 10:49am
LMAO!!!!!!
Comment by Ticklel1st on Nov 03, 2020 12:32pm
Who in their right mind is going to finance their next round of bonuses??? Howhee...what your money..get your money..keep your money. Too funny. But he must have some gag holders lined up or he would have not mentioned it.
Comment by wexworth on Nov 03, 2020 12:39pm
The Rodan launch is not there but I think due to contract restrictions on declaring any sort of target time frame on product market introduction, they may have to remain silent. So if they accomplish that as well, then that would be the moment when the ongoing revenue engine starts up and market reaction to Sirona Sirona scientific platform gauged.
Comment by forhandlaren on Nov 03, 2020 1:06pm
We actually have a time table for the R+F launch. I'm pretty sure that Howard has mentioned 15-18 months in a video interview last year. The challenge is to interpret the baseline. Did the period start by the definitive agreement?
Comment by MirrorWorldMan on Nov 03, 2020 1:10pm
One of the problems with many of the postings here are the ever present terms saying  " maybe's" , "I thinks's", "could be's" and "if's".   Hopeful speculation to support investors thesis.  Facts are rare.  Howie did not incude a launch of 1067 in his  list of 8 milestones so he does not expect it to occur.
Comment by wexworth on Nov 03, 2020 2:02pm
I am being conditional but these are confirmed facts.
Comment by JohnFriesen on Nov 04, 2020 8:46am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities